Thrombotic issues in transgender medicine: A review

American Journal of Hematology

Volumn 92, Issue 2, 2017, Pages 204-208

  Shatzel, Joseph J ^a   Connelly, Kara J ^a   DeLoughery, Thomas G ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; ANTICOAGULANT AGENT; CONJUGATED ESTROGEN; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; PROGESTERONE; SEX HORMONE; TESTOSTERONE;

ANTICOAGULATION; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; ERYTHROCYTOSIS; FEMALE TO MALE TRANSGENDER; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MALE TO FEMALE TRANSGENDER; META ANALYSIS (TOPIC); ORCHIECTOMY; POLYCYTHEMIA; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; FEMALE; HEALTH SERVICE; INCIDENCE; MALE; PROCEDURES; TRANSGENDER; VENOUS THROMBOSIS;

FEMALE; HEALTH SERVICES FOR TRANSGENDER PERSONS; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MALE; TRANSGENDER PERSONS; VENOUS THROMBOSIS;

EID: 85009773778     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24593     Document Type: Review

References (54)

1. Gates G. How many people are lesbian, gay, bisexual, and transgender? Los Angeles, CA, The Williams Institute; 2011.
2. Gardner IH, Safer JD. Progress on the road to better medical care for transgender patients. Curr Opin Endocrinol DiabetesObes 2013;20:553–558.
3. Weinand JD, Safer JD. Hormone therapy in transgender adults is safe with provider supervision: A review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol 2015;2:55–60.
4. Schuster MA, Reisner SL, Onorato SE. Beyond bathrooms—Meeting the health needs of transgender people. N Engl J Med 2016;375:101–103.
5. Tugnet N, Goddard JC, Vickery RM, et al. Current management of male-to-female gender identity disorder in the UK. Postgraduate Med J 2007;83:638–642.
6. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2009;94:3132–3154.
7. World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender nonconforming people. 7th edition. 2011; Available at: http://www.wpath.org/documents/Standards%20of%20Care% 20V27%20-%202011%202020WPATH.pdf Available at. Accessed February 14th, 2015.
8. Gooren LJ. Care of transsexual persons. N Engl J Med 2011;364:1251–1257.
9. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: A randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671–1676.
10. Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 1999;5:672–680.
11. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ (Clin Res Ed) 2008;336:1227–1231.
12. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost 2007;5:692–699.
13. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy—Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis Haemostasis 2000;84:961–967.
14. Olie V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457–463.
15. Ehdaie B, Atoria CL, Gupta A, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 2012;118:3397–3406.
16. Lundgren R, Sundin T, Colleen S, et al. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study. Scand J Urol Nephrol 1986;20:101–105.
17. Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: A case–control study. Eur J Endocrinol 2013;169:471–478.
18. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012;9:2641–2651.
19. De Cuypere G, T'Sjoen G, Beerten R, et al. Sexual and physical health after sex reassignment surgery. Arch Sex Behav 2005;34:679–690.
20. Ott J, Kaufmann U, Bentz EK, et al. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertility Sterility 2010;93:1267–1272.
21. Wilson R, Spiers A, Ewan J, et al. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas 2009;62:281–286.
22. Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European network for the investigation of gender incongruence. J Sex Med 2014;11:1999–2011.
23. Van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997;47:337–343.
24. Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav 1989;18:49–57.
25. Dittrich R, Binder H, Cupisti S, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabet Off J German Soc Endocrinol German Diabet Assoc 2005;113:586–592.
26. Schlatterer K, Yassouridis A, von Werder K, et al. A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Arch Sex Behav 1998;27:475–492.
27. Becerra FA, de Luis Roman DA, Piedrola Maroto G. Morbidity in transsexual patients with cross-gender hormone self-treatment. Med Clin 1999;113:484–487.
28. Bland LB, Garzotto M, DeLoughery TG, et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005;103:717–723.
29. Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gender Med 2005;2(SupplA):S18–S27.
30. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:209–220.
31. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979–1987.
32. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (hers ii). JAMA 2002;288:58–64.
33. Cushman M, Kuller LH, Prentice R, et al. EStrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–1580.
34. Martinelli I, Lensing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016;127:1417–1425.
35. Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: A meta-analysis. Eur Heart J 2008;29:2031–2041.
36. Asscheman H, T'Sjoen G, Lemaire A, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: A review. Andrologia 2014;46:791–795.
37. Shiffman MA. Estrogen and thromboembolic disorders: Should patients stop hormones prior to cosmetic surgery? J Women's Health 2003;12:853–855.
38. Brighouse D. Hormone replacement therapy (HRT) and anaesthesia. Br J Anaesth 2001;86:709–716.
39. Glueck CJ, Bowe D, Valdez A, Wang P. Thrombosis in three postmenopausal women receiving testosterone therapy for low libido. Women's Health (London, England) 2013;9:405–410.
40. Glueck CJ, Richardson-Royer C, Schultz R, et al. Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: An exploratory, hypothesis-generating study. Clin Appl Thromb Hemostasis Off J Int Acad Clin Appl Thromb Hemostasis 2014;20:244–249.
41. Baillargeon J, Urban RJ, Morgentaler A, et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc 2015;90:1038–1045.
42. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med 2016;374:611–624.
43. Bolour S, Braunstein G. Testosterone therapy in women: A review. Int J Impotence Res 2005;17:399–408.
44. Davis SR. Cardiovascular and cancer safety of testosterone in women. Curr Opin Endocrinol Diabet Obes 2011;18:198–203.
45. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol Ser A Biol Sci Med Sci 2005;60:1451–1457.
46. Volpi R, Coiro V, Chiodera P, et al. Extraprostatic complications of testosterone replacement therapy. J Endocrinol Investig 2005;28:(11 Suppl Proceedings):75–77.
47. Bhatt VR. Secondary polycythemia and the risk of venous thromboembolism. J Clin Med Res 2014;6:395–397.
48. Jones SD, Dukovac T, Sangkum P, et al. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev 2015;3:101–112.
49. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560–2575.
50. Coviello AD, Kaplan B, Lakshman KM, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008;93:914–919.
51. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.
52. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22–33.
53. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–124.
54. Nadeem O, Gui J, Ornstein DL. Prevalence of venous thromboembolism in patients with secondary polycythemia. Clin Appl Thromb Hemostasis Off J Int Acad Clin Appl Thromb Hemostasis 2013;19:10. 1177/1076029612460425.